• Skip to main content
  • Skip to header right navigation
  • Skip to site footer

Log in
  • Search
    • Search All SAGES Content
    • Search SAGES Guidelines
    • Search the Video Library
    • Search the Image Library
    • Search the Abstracts Archive
www.sages.org

SAGES

Reimagining surgical care for a healthier world

  • Home
    • Search
    • SAGES Home
    • SAGES Foundation Home
  • About
    • Awards
    • Who Is SAGES?
    • Leadership
    • Our Mission
    • Advocacy
    • Committees
      • SAGES Board of Governors
      • Officers and Representatives of the Society
      • Committee Chairs and Co-Chairs
      • Committee Rosters
      • SAGES Past Presidents
  • Meetings
    • SAGES NBT Innovation Weekend
    • SAGES Annual Meeting
      • 2026 Scientific Session Call for Abstracts
      • 2026 Emerging Technology Call for Abstracts
    • CME Claim Form
    • SAGES Past, Present, Future, and Related Meeting Information
    • SAGES Related Meetings & Events Calendar
  • Join SAGES!
    • Membership Application
    • Membership Benefits
    • Membership Types
      • Requirements and Applications for Active Membership in SAGES
      • Requirements and Applications for Affiliate Membership in SAGES
      • Requirements and Applications for Associate Active Membership in SAGES
      • Requirements and Applications for Candidate Membership in SAGES
      • Requirements and Applications for International Membership in SAGES
      • Requirements for Medical Student Membership
    • Member Spotlight
    • Give the Gift of SAGES Membership
  • Patients
    • Join the SAGES Patient Partner Network (PPN)
    • Patient Information Brochures
    • Healthy Sooner – Patient Information for Minimally Invasive Surgery
    • Choosing Wisely – An Initiative of the ABIM Foundation
    • All in the Recovery: Colorectal Cancer Alliance
    • Find A SAGES Surgeon
  • Publications
    • Clinical / Practice / Training Guidelines, Statements, and Standards of Practice
    • Sustainability in Surgical Practice
    • SAGES Stories Podcast
    • Patient Information Brochures
    • Patient Information From SAGES
    • TAVAC – Technology and Value Assessments
    • Surgical Endoscopy and Other Journal Information
    • SAGES Manuals
    • MesSAGES – The SAGES Newsletter
    • COVID-19 Archive
    • Troubleshooting Guides
  • Education
    • Wellness Resources – You Are Not Alone
    • Avoid Opiates After Surgery
    • SAGES Subscription Catalog
    • SAGES TV: Home of SAGES Surgical Videos
    • The SAGES Safe Cholecystectomy Program
    • Masters Program
    • Resident and Fellow Opportunities
      • MIS Fellows Course
      • SAGES Robotics Residents and Fellows Courses
      • SAGES Free Resident Webinar Series
      • Fluorescence-Guided Surgery Course for Fellows
      • Fellows’ Career Development Course
    • SAGES S.M.A.R.T. Enhanced Recovery Program
    • SAGES @ Cine-Med Products
      • SAGES Top 21 Minimally Invasive Procedures Every Practicing Surgeon Should Know
      • SAGES Pearls Step-by-Step
      • SAGES Flexible Endoscopy 101
    • SAGES OR SAFETY Video Activity
  • Opportunities
    • Fellowship Recognition Opportunities
    • SAGES Advanced Flexible Endoscopy Area of Concentrated Training (ACT) SEAL
    • Multi-Society Foregut Fellowship Certification
    • Research Opportunities
    • FLS
    • FES
    • FUSE
    • Jobs Board
    • SAGES Go Global: Global Affairs and Humanitarian Efforts
  • OWLS/FLS
You are here: Home / Abstracts / Sublingual Sufentanil for the Management of Acute Pain

Sublingual Sufentanil for the Management of Acute Pain

Forrest Ringold, MD1, Harold Minkowitz, MD2, Tong-Joo Gan, MD3, Yu-kun Chiang, PhD4, Karen DiDonato, RN, MSN5, Pamela Palmer, MD, PhD5. 1Mobile Infirmary Medical Center, 2Memorial Hermann Memorial City Medical Center, 3Stony Brook University Hospital, 4Essence Sciences, Inc., 5AcelRx Pharmaceuticals

Description of Technology: The sufentanil sublingual tablet system (Zalviso™) is a non-invasive, patient-controlled analgesia (PCA) drug/device product currently under review by the U.S. FDA and European Medicines Agency for treatment of moderate to severe acute pain in a hospital setting. A second sublingual sufentanil product (30mcg tablet), dispensed using a single-dose applicator, is also in development for treatment of acute pain in a medically-supervised setting, such as Ambulatory Surgery Centers. Sufentanil appears well-suited for acute pain management when delivered sublingually as a result of its high lipid solubility, favorable therapeutic index (as suggested in animal models) and lack of active metabolites.

Objective: The primary objective of this analysis was to examine the repeat-dose safety and efficacy of sublingual sufentanil tablets (SST) when used for post-operative pain management in both a Phase 2 ambulatory surgery population (20 mcg and 30 mcg tablets) and a Phase 3 major abdominal surgery population (15 mcg tablets). Both trials were randomized and placebo-controlled with primary efficacy measures that included the time-weighted sum of pain intensity differences (SPID) to baseline over the 12 and 48-hour study periods. Safety assessments consisted of adverse events (AE), vital signs and early termination.

Results: 101 and 178 patients were randomized in the phase 2 (P2) and phase 3 (P3) studies, respectively. SST 30 mcg was superior to placebo (PBO) for SPID12 (p=0.003) in the P2 study and SST 15mcg was superior to PBO for SPID48 (p=0.001) in the P3 study. Analysis of pain relief by evaluation time point yielded statistically significant differences in favor of SST as early as 30 minutes(p<0.001) following first dose in P2 and 45 minutes (p=0.027) following first dose in P3. AE’s in general were mild to moderate in severity and similar across all treatment assignments. The most common treatment-related AEs for patients receiving SST were nausea, vomiting, dizziness and somnolence.

Conclusions: Sufentanil tablets dispensed sublingually with a handheld PCA device or by a healthcare professional using a single-dose applicator, are in development for treatment of patients with moderate-to-severe acute pain. When administered sublingually, sufentanil’s fast onset of analgesia, non-invasive route of delivery and patient satisfaction/tolerability make it a useful alternative to IM or IV dosing.

140

Share this:

  • Click to share on X (Opens in new window) X
  • Click to share on Facebook (Opens in new window) Facebook
  • Click to share on LinkedIn (Opens in new window) LinkedIn
  • Click to share on Pinterest (Opens in new window) Pinterest
  • Click to share on WhatsApp (Opens in new window) WhatsApp
  • Click to share on Reddit (Opens in new window) Reddit
  • Click to share on Pocket (Opens in new window) Pocket
  • Click to share on Mastodon (Opens in new window) Mastodon
  • Click to share on Threads (Opens in new window) Threads
  • Click to share on Bluesky (Opens in new window) Bluesky

Related


sages_adbutler_leaderboard

Hours & Info

11300 West Olympic Blvd, Suite 600
Los Angeles, CA 90064

1-310-437-0544

[email protected]

Monday – Friday
8am to 5pm Pacific Time

Find Us Around the Web!

  • Bluesky
  • X
  • Instagram
  • Facebook
  • YouTube

Copyright © 2025 · SAGES · All Rights Reserved

Important Links

Healthy Sooner: Patient Information

SAGES Guidelines, Statements, & Standards of Practice

SAGES Manuals